Isembyld has brought a new biological target into treatment for spinal muscular atrophy: the muscle itself. The FDA approved the medicine, also called apitegromab-mstn, on September 11, 2026, for adults and children aged two and older who are currently receiving an SMN2-targeted treatment. It is the first approved SMA therapy to directly address muscle loss alongside existing treatment. The decision is confirmed by the FDA and Scholar Rock’s dated announcement.
That addition matters because protecting the nerve cells that control movement leaves another challenge: helping weakened muscles function better. The approval expands the treatment toolkit, while the evidence sets a more measured expectation than the idea of restored movement for everyone.
How Isembyld targets the muscle side of SMA
SMA begins with a faulty SMN1 gene and a shortage of a protein needed by motor neurons. SMN2-targeted medicines help the body produce more functional protein from a backup gene. Outcomes have improved, but substantial movement limitations can remain, particularly in advanced disease. The FDA’s explanation identifies that remaining muscle weakness as the gap this approval addresses.
Isembyld is an antibody that blocks activation of myostatin, a protein that restrains skeletal muscle growth. The earlier TOPAZ study explored this approach in people with later-onset SMA and helped support testing it in a larger, placebo-controlled trial. The biological rationale is to make muscle a second point of treatment alongside support for motor neurons.
The trial measured movement, not just muscle size
The pivotal SAPPHIRE trial enrolled 188 participants aged two to 21 with nonambulatory type 2 or type 3 SMA, meaning they could not walk independently. All were already receiving nusinersen or risdiplam. Its main efficacy analysis focused on 156 children aged two to 12, according to the published trial.
Researchers used the Hammersmith Functional Motor Scale Expanded, or HFMSE. The registered outcome definition describes 33 activities, each scored according to whether a person can perform it independently, with adaptation, or not at all. The maximum is 66 points. This makes the test a measure of functional ability rather than a laboratory marker or a photograph of bigger muscles.
At one year, pooling the two apitegromab doses produced a 1.8-point advantage over placebo: an average 0.6-point increase versus a 1.2-point decline. That comparison was statistically significant, with p=0.019. The higher-dose comparison alone produced a 1.4-point difference and was not statistically significant, with p=0.11. Both findings appear in the Lancet Neurology report.
The approved-dose analysis in children aged two to 12, highlighted at launch, showed a 2.2-point advantage. A gain of at least three points occurred in 34.2% of treated patients versus 13.5% receiving placebo. However, Scholar Rock explicitly marks these p-values as nominal. That means they are not adjusted for multiple comparisons; these results belong to a different analysis from the pooled-dose primary comparison. An average benefit also cannot predict an individual’s change in daily abilities.
A broad approval with a specific evidence base
The licensed population includes adults and children from age two receiving an SMN2-targeted treatment. The strongest controlled efficacy evidence comes from younger children who could not walk independently. Those facts describe different things: who the FDA has authorised treatment for, and who supplied the central trial evidence.
The prescribing information also puts fractures among the major considerations. Fractures occurred in 9% of patients in the recommended-dose group versus 2% on placebo. Serious fractures have occurred, and some events had no clear trigger such as a fall. Common adverse reactions include respiratory infections, vomiting, cough, headache and hypersensitivity. Animal data also raise concerns about fetal harm and reproductive effects.
For SMA research, the milestone is evidence that targeting muscle can add functional benefit to an established treatment approach. Longer follow-up and experience across the approved population will be important for understanding how that benefit holds up, how it translates into everyday life, and how it balances against the risks.
Featured image: Laboratory research, shown for illustration. Photo by Julia Koblitz on Unsplash.
Leave a Reply